Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 108 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $272,924 | +124.5% | 40,195 | +65.7% | 0.00% | – |
| Q1 2023 | $121,568 | -62.6% | 24,265 | -63.6% | 0.00% | – |
| Q4 2022 | $325,257 | +82.7% | 66,651 | +438.6% | 0.00% | – |
| Q3 2022 | $178,000 | -75.4% | 12,375 | -72.3% | 0.00% | – |
| Q4 2021 | $724,000 | +38.4% | 44,673 | +144.0% | 0.00% | – |
| Q3 2021 | $523,000 | +139.9% | 18,311 | +154.2% | 0.00% | – |
| Q1 2021 | $218,000 | -78.6% | 7,204 | -65.0% | 0.00% | -100.0% |
| Q4 2020 | $1,020,000 | +200.0% | 20,607 | +132.5% | 0.00% | – |
| Q3 2020 | $340,000 | +10.0% | 8,864 | +23.9% | 0.00% | – |
| Q2 2020 | $309,000 | – | 7,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |